

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine

Tamara Rothenburger¹, Katie-May McLaughlin², Tobias Herold^{3,4}, Constanze Schneider^{1,10}, Thomas Oellerich^{5,6,7}, Florian Rothweiler¹, Andrew Feber⁸, Tim R. Fenton², Mark N. Wass², Oliver T. Keppler⁹, Martin Michaelis^{2*}, Jindrich Cinatl jr.^{1*}

¹Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Frankfurt am Main, Germany

²School of Biosciences, University of Kent, Canterbury, UK

³Department of Medicine III, University Hospital, LMU Munich, Germany

⁴Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany

⁵Department of Medicine II, Hematology/Oncology, Goethe-Universität, Frankfurt am Main, Germany

⁶Frankfurt Cancer Institute, Goethe University, Germany

⁷German Cancer Consortium/German Cancer Research Center, Heidelberg, Germany

⁸Division of Surgery and Interventional Science, University College London, UK

⁹Max von Pettenkofer Institute, Virology, Faculty of Medicine, LMU München, Munich, Germany

¹⁰Current affiliation: Department of Medicine II, Hematology/Oncology, Goethe-Universität, Frankfurt am Main, Germany; Frankfurt Cancer Institute, Goethe University, Germany

* Corresponding authors: Jindrich Cinatl jr. (Cinatl@em.uni-frankfurt.de); Martin Michaelis (M.Michaelis@kent.ac.uk)

Abstract

The nucleoside analogue nelarabine, the prodrug of arabinosylguanine (AraG), has been known for decades to be effective against acute lymphoblastic leukaemias of T-cell (T-ALL), but not of B-cell (B-ALL) origin. The mechanisms underlying this lineage-specific drug sensitivity have remained elusive. Data from pharmacogenomics studies and from a panel of ALL cell lines revealed an inverse correlation of *SAMHD1* expression and nelarabine sensitivity. *SAMHD1* can hydrolyse and thus inactivate triphosphorylated nucleoside analogues. Transcriptomic and protein expression profiling of cell lines and patient-derived leukaemic blasts revealed lower *SAMHD1* abundance in T-ALL than in B-ALL. Mechanistically, *SAMHD1* promoter methylation strongly correlated with suppressed *SAMHD1* expression, while T-ALL cells did not display increased global DNA methylation. Targeted *SAMHD1* degradation using virus-like particles containing Vpx sensitised B-ALL cells to AraG, while ectopic *SAMHD1* expression in *SAMHD1*-null T-ALL cells induced AraG resistance. *SAMHD1* had a larger impact on cytarabine activity than on nelarabine/ AraG activity in acute myeloid leukaemia (AML) cells, but more strongly affected nelarabine/ AraG activity in ALL cells. This indicates a critical role of the cancer entity. In conclusion, lineage-specific differences in *SAMHD1* promoter methylation and, in turn, *SAMHD1* expression levels determine ALL cell response to nelarabine. *SAMHD1* is a potential biomarker for the identification of ALL patients likely to benefit from nelarabine therapy and a therapeutic target to overcome nelarabine resistance.

Introduction

Acute lymphoblastic leukaemia (ALL) cells originate from precursor lymphoid T- (T-ALL) and B-cells (B-ALL). In children, ALL is the most common cancer associated with high cure rates of about 85%. In adults, ALL accounts for 15-25% of acute leukaemias and is associated with a less favourable outcome [Mohseni et al., 2018, Cocco et al., 2019; Follini et al., 2019; Pavlovic et al., 2019]. Among ALLs, T-ALL is responsible for approximately 15% of paediatric ALLs and 25% of adult ALLs [Follini et al., 2019]. Nelarabine displays selective activity in T-ALL over B-ALL and is used for the treatment of relapsed and refractory T-ALL but not routinely for the treatment of B-ALL [Cohen et al., 1983; Shewach and Mitchell, 1989; Jabbour et al., 2015; Kadia and Gandhi, 2017; Kantarjian et al., 2017; Marks and Rowntree, 2017; Zwaan et al., 2017; Jabbour et al., 2018; Follini et al., 2019; Teachey and O'Connor, 2019]. However, the molecular mechanisms underlying this difference remain elusive. Moreover, nelarabine therapy can be associated with irreversible life-threatening neurotoxicity [Berg et al., 2005; Kadia and Gandhi, 2017]. Hence, biomarkers indicating patients who are most likely to benefit from nelarabine therapy are needed.

Here, we used an approach that combined data from the large pharmacogenomics screens Cancer Therapeutics Response Portal (CTRP), Cancer Cell Line Encyclopedia (CCLE), and Genomics of Drug Sensitivity in Cancer (GDSC) with data from an ALL cell line panel derived from the Resistant Cancer Cell Line (RCCL) collection and patient data to investigate the mechanisms underlying the discrepancy in the nelarabine sensitivity between T-ALL and B-ALL. The results show that low expression of Sterile alpha motif and histidine-aspartic acid domain-containing protein 1 (SAMHD1) in T-ALL cells is a key determinant of nelarabine sensitivity and

that SAMHD1 is a potential biomarker and therapeutic target for the improvement of nelarabine-based therapies for both T-ALL and B-ALL patients.

Results

Gene expression and pathway analysis to compare T-ALL and B-ALL cells

To identify potential differences between T-ALL and B-ALL that may explain the observed discrepancies in nelarabine sensitivity, we started by analysing data derived from the large pharmacogenomics databases Cancer Cell Line Encyclopedia (CCLE) [Barretina et al., 2012], Cancer Therapeutics Response Portal (CTRP) [Basu et al., 2013], and Genomics of Drug Sensitivity in Cancer (GDSC) [Yang et al., 2013]. The CCLE contained data derived from 34 leukaemia cell lines (18 B-ALL, 16 T-ALL) and the GDSC from 38 leukaemia cell lines (21 B-ALL, 17 T-ALL), with an overlap of 19 cell lines (Suppl. Table 1). The CCLE and CTRP used the same cell line panel for their studies [Basu et al., 2013].

Nelarabine was tested in 24 ALL (11 B-ALL, 13-T-ALL) cell lines in the CTRP (Suppl. Table 2). In agreement with the available literature [Cohen et al., 1983; Shewach and Mitchell, 1989; Beesley et al., 2007; Homminga et al., 2011], nelarabine displayed higher activity in T-ALL than in B-ALL cell lines (Figure 1A, Suppl. Table 2).

Initially, we compared transcriptomics data (mRNA abundance) between T-ALL and B-ALL cell lines. Substantial proportions of transcripts displayed significant differences ($P < 0.05$) in their abundance levels between T-ALL and B-ALL cells in the GDSC (3,998/ 22.5% of 17,735 transcripts), CCLE (8,498/ 42.1% of 20,172 transcripts), and CTRP (4,507/ 24.3% of 18,539 transcripts) (Suppl. Table 3). Gene expression heatmaps illustrated these differences (Figure 1B, Suppl. Figure 1), but manual analysis of the top differentially regulated genes did not result in the identification of candidate genes, whose expression seemed likely to be responsible for the observed differences in nelarabine sensitivity.

A pathway analysis using the PANTHER database (Protein ANalysis THrough Evolutionary Relationships, <http://pantherdb.org>) [Mi et al., 2019] also did not reveal processes that may underlie the increased nelarabine sensitivity of T-ALL cells (Figure 1C, Suppl. Figure 2). As expected, B-cell- and T-cell-specific processes featured prominently among the most strongly differentially regulated pathways.

***SAMHD1* expression levels correlate with resistance to nelarabine and are lower in T-ALL than in B-ALL cells**

The correlation of transcriptomics data with the nelarabine drug response, represented as AUC, identified *SAMHD1* as the gene, whose expression displayed the most significant direct correlation (Suppl. Table 4). Analysis of *SAMHD1* expression exclusively in either the B-ALL or T-ALL subset also showed a highly significant direct correlation with the nelarabine AUC (Suppl. Table 4). Furthermore, when we correlated drug AUCs with *SAMHD1* expression, nelarabine displayed the most significant direct correlation with *SAMHD1* expression across all ALL cell lines, the second most significant direct correlation with *SAMHD1* expression in the B-ALL cell lines, and the third most significant direct correlation with *SAMHD1* expression in the T-ALL cell lines (Suppl. Table 5).

SAMHD1 is a deoxynucleotide triphosphate (dNTP) hydrolase that cleaves physiological dNTPs and triphosphorylated nucleoside analogues [Arnie et al., 2013; Ballana et al., 2014; Hollenbaugh et al., 2017; Knecht et al., 2018; Mauney and Hollis, 2018]. It was previously shown to interfere with the activity of anti-cancer nucleoside analogues including nelarabine [Herold et al., 2017; Hollenbaugh et al., 2017; Knecht et al., 2018]. If *SAMHD1* was responsible for the differences observed in nelarabine sensitivity between T-ALL and B-ALL, T-ALL cells would be expected to express lower

levels of *SAMHD1*. Indeed, the *SAMHD1* expression (mRNA abundance) levels were significantly lower in T-ALL than in B-ALL cell lines in all three databases (Figure 2A). Similar findings were detected in a gene expression dataset derived from blasts of 306 ALL (222 B-ALL, 84 T-ALL) patients [Herold et al., 2014; 2017] (Figure 2B; Suppl. Figure 3).

A number of other gene products have been described to be involved in the transport, activation, and metabolism of nucleoside analogues such as nelarabine, including DCK, DGUOK, SLC29A1 (ENT1), SLC29A2 (ENT2), NT5C, NT5C2, PNP, RRM1, RRM2, and SLC22A4 (OCTN1) [Homminga et al., 2011; Drenberg et al., 2017]. While statistically significant differences in the expression of some of the respective genes were noted between B-ALL and T-ALL cell lines in some of the three datasets, none was consistent across all three and none was as robust as in the expression of *SAMHD1* (Figure 2C, Suppl. Figure 4). Moreover, only the expression of *SAMHD1* correlated with the nelarabine AUC (Figure 3, Suppl. Figure 5). This shows that *SAMHD1* is a critical determinant of nelarabine efficacy in ALL and that low *SAMHD1* levels explain the specific nelarabine sensitivity of T-ALL cells.

***SAMHD1* expression levels do not correlate with cytarabine resistance in ALL**

Cellular *SAMHD1* levels have previously been shown to critically determine cytarabine efficacy in acute myeloid leukaemia (AML) cells [Hollenbaugh et al., 2017; Schneider et al., 2017; Knecht et al., 2018]. The CTRP and GDSC contained data on cytarabine activity. In contrast to AML cells, however, there was no difference in the cytarabine sensitivity between B-ALL and T-ALL cell lines and no correlation between *SAMHD1* expression and cytarabine sensitivity in ALL cells (Figure 3, Suppl. Figure

6). Hence, the effect of SAMHD1 on nucleoside analogue activity depends on the tissue context.

SAMHD1 mRNA levels largely predict SAMHD1 protein levels in ALL cell lines

To further investigate the role of SAMHD1 on nelarabine and cytarabine efficacy in ALL, we assembled a panel consisting of 15 B-ALL and 11 T-ALL cell lines from the Resistant Cancer Cell Line (RCCL) collection [Michaelis et al., 2019] (Suppl. Table 6). Firstly, we investigated the extent to which cellular SAMHD1 mRNA levels are indicative of cellular protein levels. Western blot analyses confirmed that the RCCL T-ALL cell lines generally display lower SAMHD1 protein levels than the RCCL B-ALL cell lines (Figure 4A). However, quantitative Western blot analysis and quantitative PCR (qPCR) showed that cellular SAMHD1 mRNA levels do not always directly correlate with cellular SAMHD1 protein levels (Figure 4B). This is likely to reflect the complexity of the regulation of protein levels, which are determined by transcription and translation efficacy, factors that control mRNA stability (e.g. microRNAs and proteins that control mRNA degradation), and post-translational modifications that promote (proteasomal) protein degradation [Radhakrishnan and Green, 2016; Bicknell and Ricci, 2017; Dikic, 2017; Jaén et al., 2018; Ko and Dixon, 2018; Wolf and Menssen, 2018]. Moreover, mutations may affect SAMHD1 function, as demonstrated in patients with chronic lymphocytic leukaemia and colorectal cancer [Clifford et al., 2014; Rentoft et al., 2016]. However, the only ALL cell line with a *SAMHD1* mutation was Jurkat, which harboured an R611* nonsense mutation based on GDSC data. SAMHD1 mRNA and protein levels in the RCCL are correlated with SAMHD1 mRNA levels in the corresponding cell lines from CTRP, CCLE and GDSC (Suppl. Figure 7).

Hence, SAMHD1 mRNA levels, largely predict SAMHD1 protein levels, which is in line with previous findings [Schneider et al., 2017].

Next, the sensitivity of the RCCL ALL cell lines was tested against arabinosylguanine (AraG), the product of the prodrug nelarabine [Curbo and Karlsson, 2006] and cytarabine. The results were in agreement with the CTRP data showing that T-ALL cell lines were significantly more sensitive to AraG than B-ALL cell lines (Figure 5, Suppl. Table 6). Notably, there was a significant correlation between the nelarabine AUCs in the CTRP and the AraG IC50s in the RCCL panel among the cell lines that were present in both datasets (Suppl. Figure 8). In contrast to the CTRP and GDSC data that had not indicated a difference between the cytarabine sensitivity of T-ALL- and B-ALL- cells, T-ALL cell lines displayed a trend indicating increased sensitivity to cytarabine ($P = 0.055$) (Figure 5). SAMHD1 protein levels displayed a significant correlation with the AraG concentrations that reduced cell viability by 50% (IC50) in all ALL cell lines and the lineage-specific sunanalyses (Figure 5). In contrast, a significant correlation between SAMHD1 protein levels and cytarabine activity was only detected across all ALL cell lines but not when only B-ALL or T-ALL cell lines were considered (Figure 5). SAMHD1 mRNA levels were correlated with the AraG IC50 across all ALL cell lines and T-ALL cell lines but not B-ALL cell lines ($P = 0.1095$) (Figure 5). No significant correlation was detected between the SAMHD1 mRNA levels and the cytarabine IC50 in the RCCL ALL cell lines (Figure 5).

Taken together, these results confirm the CTRP data in showing that cellular SAMHD1 levels determine ALL sensitivity against AraG, the product of nelarabine, and that low SAMHD1 levels in T-ALL cells are associated with specific nelarabine/Ara-G activity in this lineage. In contrast to the CTRP and GDSC data, the additional

experimental analyses in the RCCL ALL cell line panel suggest that SAMHD1 levels may also affect cytarabine activity in ALL, albeit to a lower degree than AraG activity.

SAMHD1 depletion sensitises ALL cells more strongly to AraG than to cytarabine

To further investigate the functional role of SAMHD1 in determining AraG and cytarabine activity in ALL cells, we depleted SAMHD1 using virus-like particles containing Vpx as previously described [Baldauf et al., 2012; Schneider et al., 2017]. Vpx is a protein encoded by HIV-2 and certain SIV strains that mediates proteasomal SAMHD1 degradation [Hrecka et al., 2011; Laguette et al., 2011; Baldauf et al., 2012]. Vpx virus-like particles resulted in the sensitisation of ALL cells to AraG and cytarabine but exerted much more pronounced effects on the activity of AraG [Figure 6A].

In the ALL cell lines MHH-CALL-4, SEM, and TANOUE, the AraG IC₅₀s were between 37- and 112-fold lower following exposure to Vpx virus-like particles compared to Vpr virus-like particles, which served as negative controls. In contrast, Vpx virus-like particles only reduced the cytarabine IC₅₀s by 5- and 7-fold lower in these cell lines.

Differential role of SAMHD1 as resistance factor for AraG and cytarabine in ALL compared to AML

In AML cells, SAMHD1 has been described as a critical regulator of cytarabine activity [Schneider et al., 2017]. Since, Vpx virus-like particle-mediated SAMHD1 depletion had resulted in a more pronounced sensitisation of ALL cells to AraG than to cytarabine, we further compared the effect of the presence or absence of functional SAMHD1 on the activity of these structurally related nucleoside analogues in these

two types of acute leukaemia. Cell models included the *SAMHD1*-expressing AML cell line THP-1 and its subline, in which the *SAMHD1* gene had been disrupted by CRISPR/Cas9 (THP-1- KO). Further, we investigated the *SAMHD1* low/ non-expressing cell lines HEL (AML) and Jurkat (T-ALL) and their respective sublines transduced either with wild-type (WT) *SAMHD1* or the triphosphohydrolase-defective mutant *SAMHD1-D311A*. In the AML cell lines, absence of functional SAMHD1 was associated with a 47-fold (THP-1/ THP-1-KO) and 65-fold (HEL-SAMHD1_WT/HEL-SAMHD1_D311A) sensitisation to cytarabine, but only a seven- and four-fold sensitisation to AraG (Figure 6B). The T-ALL cell line Jurkat-SAMHD1_D311A was 98 times more sensitive to AraG than Jurkat-SAMHD1_WT, while JURKAT-SAMHD1_D311A was only 10 times more sensitive to cytarabine (Figure 6B). In summary, SAMHD1 activity critically regulates cytarabine activity but has a much lower impact on AraG in AML cells. The opposite effect is observed in ALL cells, in which SAMHD1 crucially determines AraG activity but exerts substantially less pronounced effects on cytarabine activity. This further confirms that the cellular background critically determines the importance of SAMHD1 as regulator of nucleoside activity.

High *SAMHD1* promoter methylation in T-ALL but not B-ALL cell lines

SAMHD1 levels may be regulated by *SAMHD1* promoter methylation in leukaemia cells [de Silva et al., 2013; Oellerich et al., 2019]. Therefore, we compared *SAMHD1* promoter methylation in T-ALL and B-ALL cell lines through amplification of a single PCR product (993-bp) corresponding to the promoter sequence after HpaII digestion. Results indicated that the SAMHD1 promoter was methylated in all T-ALL cell lines but one (MOLT-16) (Figure 7A), which was the only T-ALL cell line

characterised by high *SAMHD1* mRNA and protein levels (Figure 4) and low AraG sensitivity (Suppl. Table 6). In contrast, *SAMHD1* promoter methylation was only observed in two out of 15 B-ALL cell lines (NALM-6, TOM-1) (Figure 7A). In agreement, *SAMHD1* promoter methylation was also significantly higher in T-ALL than in B-ALL cells in the GDSC and inversely correlated with *SAMHD1* expression (Figure 7B). Notably, global DNA methylation did not differ between T-ALL and B-ALL cell lines (Figure 7C), suggesting lineage-specific differences. Taken together, this suggests that the differences in cellular *SAMHD1* levels observed between T-ALL and B-ALL cell lines are to a large extent caused by differences in *SAMHD1* promoter methylation.

Discussion

Similar chemotherapeutic agents are used to treat T-ALL and B-ALL. However, nelarabine is specifically used for relapsed T-ALL [Jabbour et al., 2015; 2018; Kadia and Gandhi, 2017; Kantarjian et al., 2017; Marks and Rowntree, 2017; Zwaan et al., 2017; Follini et al., 2019]. Although it had been known for decades that nelarabine is more active in T-ALL than in B-ALL cells [Verhoef and Fridland, 1985; Shewach and Mitchell, 1989], the underlying mechanisms had remained elusive.

Here, we used an approach combining data derived from large pharmacogenomics screens (CTRP, CCLE, GDSC), an RCCL-derived ALL cell line panel, and patient data and found that cellular SAMHD1 levels critically determined ALL cell sensitivity to nelarabine and AraG. Nelarabine is metabolised into AraG, which is then triphosphorylated by cellular kinases into the active form [Curbo and Karlsson, 2006]. SAMHD1 is a deoxynucleotide triphosphate (dNTP) hydrolase that cleaves and inactivates triphosphorylated nucleoside analogues including triphosphorylated AraG [Hollenbaugh et al., 2017; Knecht et al., 2018; Mauney and Hollis, 2018; Oellerich et al., 2019]. Moreover, T-ALL cells were characterised by substantially lower SAMHD1 levels than B-ALL cells. Previous studies had demonstrated an association between AraG efficacy and AraG triphosphate levels in leukaemia cells, but the mechanism determining AraG triphosphate levels had remained unknown [Verhoef and Fridland, 1985; Shewach and Mitchell, 1989, Homminga et al., 2011; Akahane et al., 2019]. Hence, SAMHD1 is the missing link explaining the discrepancy in nelarabine sensitivity between T-ALL and B-ALL.

Notably, SAMHD1 has also been shown to promote DNA damage repair including damage induced by the topoisomerase inhibitors camptothecin and etoposide [Daddacha et al., 2014]. Thus, SAMHD1-mediated repair of nelarabine/

AraG-induced DNA damage may potentially also contribute to the increased nelarabine/ AraG resistance associated with high SAMHD1 levels in ALL cells. However, *SAMHD1* expression was not associated with generally increased resistance to DNA damaging agents in the CTRP (Suppl. Table 5). The AUC of the PARP inhibitor veliparib was correlated with *SAMHD1* expression, but the AUC of the PARP inhibitor olaparib was not. The AUCs of etoposide and other prominent DNA damaging agents such as the alkylating agents temozolomide, ifosfamide, and dacarbazine and the nucleoside analogue 5-fluorouracil also were also not correlated with *SAMHD1* expression, and the AUCs of the alkylating agents cyclophosphamide and chlorambucil, the nucleoside analogue gemcitabine, the DNA cross-linker mitomycin C, and the topoisomerase inhibitor doxorubicin displayed a significant inverse correlation to *SAMHD1* expression (Suppl. Table 5). These data do not suggest that SAMHD1 interferes with the effects of anti-cancer drugs predominantly via promotion of DNA damage repair.

Data derived from the RCCL ALL cell line panel as well as from the GDSC indicate that the differences in *SAMHD1* expression observed between T-ALL and B-ALL cells are at least in part the consequence of higher SAMHD1 promoter methylation in T-ALL than in B-ALL cells. Thus, SAMHD1 expression levels and SAMHD1 promoter methylation are potential biomarkers of nelarabine sensitivity that deserve further clinical investigation. Based on our current data, patients suffering from ALL characterised by high SAMHD1 expression are unlikely to benefit from therapy using nelarabine and may be better treated with ribose-based thiopurines that are no SAMHD1 substrates, such as 6-thioguanine or 6-mercaptopurine [Wu and Li, 2018].

SAMHD1 depletion sensitised ALL cells to AraG, indicating that SAMHD1 may also serve as a therapeutic target to improve nelarabine therapies in ALL patients. Notably, both T-ALL and B-ALL patients may benefit from SAMHD1 inhibition in combination with nelarabine therapy. Interestingly, the effect of SAMHD1 on the activity of nucleoside analogues varied substantially between different forms of leukaemia. SAMHD1 was previously shown to critically determine the activity of the nucleoside analogue cytarabine in AML [Hollenbaugh et al., 2017; Schneider et al., 2017; Knecht et al., 2018]. Compared to the pronounced effects of SAMHD1 on nelarabine/ AraG activity in ALL, however, SAMHD1 exerted only minor effects on the activity of cytarabine in this leukaemia type. Interestingly, the situation was reversed in AML cells, where SAMHD1 critically affected cytarabine activity but had much lower impact on AraG. These findings are important, because they illustrate that, despite a general trend in the biomedical community towards tumour-agnostic approaches, which consider cancer-specific alterations independently of the cancer type [Luoh and Flaherty, 2018; Huang and Feng, 2019], a much more in depth understanding of the molecular make-up of cancer cells will be required, before therapy decisions can be entirely based on molecular markers without taking the cancer entity into consideration.

In conclusion, our data indicate that cellular SAMHD1 levels critically determine ALL cell sensitivity to nelarabine/ AraG and that T-ALL cells display lower SAMHD1 levels than B-ALL. This provides a solution to a decades old conundrum providing a mechanistic explanation for the higher nelarabine sensitivity of T-ALL cells compared to B-ALL cells. Hence, SAMHD1 has potential as a biomarker for the more accurate identification of ALL patients, who are likely to benefit from nelarabine therapy.

Moreover, SAMHD1 is a therapeutic target for the design of improved nelarabine-based treatment strategies for ALL patients.

Methods

Bioinformatics analysis of data from pharmacogenomics screens

ALL cell line drug sensitivity data and RMA-normalised gene expression values were obtained from the CCLE (2015 release, <https://portals.broadinstitute.org/ccle>), which contains data from 34 ALL cell lines (18 B-ALL and 16 T-ALL) [Barretina et al., 2012], GDSC (2016 release, <https://www.cancerrxgene.org/>; 21 B-ALL/ 17 T-ALL cell lines) [Yang et al., 2013], and CTRP (version 2, 2015 release, <https://ocg.cancer.gov/programs/ctd2/data-portal>; 11 B-ALL/ 13 T-ALL cell lines) [Basu et al., 2013].

Gene expression was compared using the Mann-Whitney U (Wilcoxon) test for independent groups. Multiple test correction of p-values was performed using the Benjamini Hochberg (BH) procedure [Benjamini and Hochberg, 1995], with a false discovery rate (FDR) of 0.05 ($BH = (\text{rank}/n) * \text{FDR}$, where n = the total number of genes compared). Gene expression levels between B-ALL and T-ALL cell lines were visualised using the ggboxplot function in R. Heatmaps showing gene expression levels were generated using the ggplot2 package in R.

36 of the ALL cell lines (19 B-ALL, 17 T-ALL) in the GDSC and 22 ALL cell lines (10 B-ALL, 12 T-ALL) in the CTRP were treated with cytarabine. 23 ALL cell lines (11 B-ALL, 12 T-ALL) in the CTRP were treated with nelarabine. Scatter plots and their associated Pearson correlations for each drug AUCs against gene expression were calculated using the ggplot2 package in R.

Expression of 18,542 genes was correlated with the nelarabine AUC in ALL cell lines and SAMHD1 expression was correlated with the AUC values of 441 drugs tested in ALL cell lines using the CTRPv2 dataset. Pearson correlation coefficients were calculated using the cor.test function in R. P-values for each correlation were ranked

and multiple test correction was performed (Benjamini-Hochberg procedure, FDR=0.05).

Pathway analysis was performed using the PANTHER (version 14.1) Overrepresentation Test [Mi et al., 2019] based on genes significantly differentially expressed in B-ALL and T-ALL cell lines after Benjamini-Hochberg p-value correction (FDR = 0.05). Fisher's exact test was applied to calculate over- vs. underrepresentation of classes. Heatmaps were prepared using the ggplot2 package in R.

Beta values for CpG sites in the SAMHD1 promoter derived from the GDSC (Gene Expression Omnibus ID GSE68379) were correlated with SAMHD1 expression in ALL cell lines.

Analysis of patient data

SAMHD1 gene expression was analyzed in publicly available Microarray data of 306 primary adult B- and T-ALL patients (Gene Expression Omnibus ID GSE66006) [Herold et al., 2017]. The median percentage of leukemic cells in the samples was 90%.

Drugs

Cytarabine was purchased from Tocris Biosciences (via Bio-Techne GmbH, Wiesbaden, Germany), AraG from Jena Bioscience (Jena, Germany).

Cell lines

The human ALL cell lines 697, ALL-SIL, BALL-1, CTV-1, GRANTA-452, HAL-01, HSB-2, JURKAT, KE-37, MHH-CALL-4, MN-60, MOLT-4, MOLT-16, NALM-6,

NALM-16, P12-ICHIKAWA, REH, ROS-50, RPMI-8402, RS4;11, SEM, TANOUE, and TOM-1 and the AML cell lines THP-1 and HEL were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany). The ALL cell lines CCRF-CEM and JJHan were received from ATCC (Manassas, VA, US) and the ALL cell line KARPAS231 from Cambridge Enterprise Ltd. (Cambridge, UK).

THP-1 cells deficient in SAMHD1 (THP-1 KO) and control cells (THP-1 Ctr.) were generated using CRISPR/Cas9 approach as previously described [Wittmann et al., 2015; Schneider et al., 2017; Oellerich et al., 2019]. THP-1 cells were plated at a density of 2×10^5 cells per ml. After 24 h, 2.5×10^6 cells were resuspended in 250 μ l Opti-MEM, mixed with 5 μ g CRISPR/Cas plasmid DNA, and electroporated in a 4-mm cuvette using an exponential pulse at 250 V and 950 mF utilizing a Gene Pulser electroporation device (Bio-Rad Laboratories). We used a plasmid encoding a CMV-mCherry-Cas9 expression cassette and a human *SAMHD1* gene specific gRNA driven by the U6 promoter. An early coding exon of the *SAMHD1* gene was targeted using the following gRNA construct: 5'-CGGAAGGGGTGTTTGAGGGG-3'. Cells were allowed to recover for 2 days in 6-well plates filled with 4 ml medium per well before being FACS sorted for mCherry-expression on a BD FACS Aria III (BD Biosciences). For subsequent limiting dilution cloning, cells were plated at a density of 5, 10, or 20 cells per well of nine round-bottom 96-well plates and grown for 2 weeks. Plates were scanned for absorption at 600 nm and growing clones were identified using custom software and picked and duplicated by a Biomek FXp (Beckman Coulter) liquid handling system.

The HEL and JURKAT SAMHD1-WT and SAMHD1-D311A cell lines were generated by co-transfection of the packaging vector pPAX2 (Addgene), either pHR-

SAMHD1-WT or pHR-SAMHD1-D311A and a plasmid encoding VSV-G, as previously described [Oellerich et al., 2019]. All cell lines were routinely tested for Mycoplasma, using the MycoAlert PLUS assay kit from Lonza, and were authenticated by short tandem repeat profiling, as described elsewhere.

All cell lines were cultured in IMDM (Biochrom) supplemented with 10% FBS (Sigma-Aldrich), 4 mM L-glutamine (Sigma-Aldrich), 100 IU per ml penicillin (Sigma-Aldrich), and 100 µg per ml streptomycin (Sigma-Aldrich) at 37 °C in a humidified 5% CO₂ incubator.

Viability assay

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay modified after Mosman [Mosman, 1983], as previously described [Onafuye et al., 2019]. Cells suspended in 100 µL cell culture medium were plated per well in 96-well plates and incubated in the presence of various drug concentrations for 96 h. Then, 25 µL of MTT solution (2 mg/mL (w/v) in PBS) were added per well, and the plates were incubated at 37 °C for an additional 4 h. After this, the cells were lysed using 200 µL of a buffer containing 20% (w/v) sodium dodecylsulfate in 50% (v/v) N,N-dimethylformamide with the pH adjusted to 4.7 at 37 °C for 4 h. Absorbance was determined at 570 nm for each well using a 96-well multiscanner. After subtracting of the background absorption, the results are expressed as percentage viability relative to control cultures which received no drug. Drug concentrations that inhibited cell viability by 50% (IC₅₀) were determined using CalcuSyn (Biosoft, Cambridge, UK).

Western blotting

Western blotting was performed as previously described [Schneider et al., 2017]. Cells were lysed in Triton X-100 sample buffer and proteins separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were blotted on a nitrocellulose membrane (Thermo Scientific). The following primary antibodies were used at the indicated dilutions: SAMHD1 (Proteintech, 1:1000), β -actin (BioVision via BioCat, 1:2000), pSAMHD1 (Cell Signaling, 1:1000), and GAPDH (Trevigen, 1:5000). Visualisation and quantification were performed using IRDye-labeled secondary antibodies (LI-COR Biotechnology) according to the manufacturer's instructions. Band volume analysis was conducted by Odyssey LICOR.

mRNA analysis

RNA extraction and TaqMan-based mRNA quantification of SAMHD1 (assay no. Hs00210019_m1) and RNaseP (TaqMan® RNaseP Assay (A30065)) as endogenous reference control were performed according to the manufacturer's protocol (Applied Biosystems). Total RNA was extracted using the RNeasy Kit from Qiagen and stored at -80°C until use. Relative quantitative PCR analyses were performed on the QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems). SAMHD1 mRNA expression levels were quantified by using the $\Delta\Delta\text{Ct}$ method with RNaseP mRNA as an endogenous reference control. All samples were run in triplicate. Data analysis was conducted using the QuantStudio System Software (Applied Biosystems).

SAMHD1 promoter methylation

SAMHD1 promoter methylation was determined as previously described [Oellerich et al., 2019]. *SAMHD1* promoter contains five *HpaII* sites surrounding the transcription start site [de Silva et al., 2013]. Methylation of the *HpaII* sites in the *SAMHD1* promoter would prevent digestion by the *HpaII*, and the intact sequence would serve as a template for PCR amplification using *SAMHD1* promoter-specific primers that flank the *HpaII* sites. To measure methylation of the *SAMHD1* promoter genomic DNA was treated with the methylation-sensitive *HpaII* endonuclease or left untreated as described previously with some modifications [de Silva et al., 2013]. PM3.fwd: TTCCGCCTCATTCGTCCTTG and PM3.rev: GGTTCTCGGGCTGTCATCG were used as *SAMHD1* promoter-specific primers. A single PCR product (993-bp) corresponding to the *SAMHD1* promoter sequence was obtained from untreated genomic DNA and treated DNA from cells with methylated but not from cells with unmethylated *SAMHD1* promoter. To serve as input control, a 0.25-kb fragment of the *GAPDH* gene lacking *HpaII* sites was PCR-amplified using the same template DNA [de Silva et al., 2013].

Manipulation of cellular SAMHD1 levels using Vpx virus-like particles

Cells were spinoculated with VSV-G pseudotyped virus-like particles carrying either Vpx or Vpr from SIVmac251, produced by co-transfection of 293T cells with pSIV3 + gag pol expression plasmids and a plasmid encoding VSV-G as previously described [Schneider et al., 2017; Oellerich et al., 2019].

Statistics

Pearson's correlation coefficient was used to compute correlations between variables, using a t-test to assess significance of the correlation.

Acknowledgements

The authors thank Sebastian Grothe, Anja Hüttinger, Lena Stegmann, and Eva Wagner for technical assistance. The work was supported by the Frankfurter Stiftung für krebskranke Kinder and the Hilfe für krebskranke Kinder Frankfurt e.V. Tobias Herold is supported by the Physician Scientists Grant (G-509200-004) from the Helmholtz Zentrum München.

Competing interests

The Johann Wolfgang Goethe University has filed a patent application, on which T.O., C.S., O.T.K. and J.C. are listed as inventors. All other authors declare no competing interests.

Availability of data and materials

All data are provided in the manuscript and the supplements.

References

Akahane K, Murakami Y, Kagami K, Abe M, Harama D, Shinohara T, Watanabe A, Goi K, Nishi R, Yamauchi T, Kimura S, Takita J, Look AT, Minegishi M, Sugita K, Inukai T. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia. *Hematol Oncol*. 2019 Oct;37(4):516-519. doi: 10.1002/hon.2654.

Amie SM, Daly MB, Noble E, Schinazi RF, Bambara RA, Kim B. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. *J Biol Chem*. 2013 Jul 12;288(28):20683-91. doi: 10.1074/jbc.M113.472159.

Ballana E, Badia R, Terradas G, Torres-Torronteras J, Ruiz A, Pauls E, Riveira-Muñoz E, Clotet B, Martí R, Esté JA. SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. *Antimicrob Agents Chemother*. 2014 Aug;58(8):4804-13.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palesscandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*. 2012 Mar 28;483(7391):603-7. doi: 10.1038/nature11003.

Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. *Cell*. 2013 Aug 29;154(5):1151-1161. doi: 10.1016/j.cell.2013.08.003.

Beesley AH, Palmer ML, Ford J, Weller RE, Cummings AJ, Freitas JR, Firth MJ, Perera KU, de Klerk NH, Kees UR. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. *Br J Haematol*. 2007 Apr;137(2):109-16.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of The Royal Statistical Society Series B* 1995;57(1):289-300.

Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. *J Clin Oncol*. 2005 May 20;23(15):3376-82.

Bicknell AA, Ricci EP. When mRNA translation meets decay. *Biochem Soc Trans*. 2017 Apr 15;45(2):339-351. doi: 10.1042/BST20160243.

Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Wright Colopy G, Dreau H, Sigaux F, Judde JG, Rotger M, Telenti A, Lin YL, Pasero P, Maelfait J, Titsias M, Cohen DR, Henderson SJ, Ross MT, Bentley D, Hillmen P, Pettitt A, Rehwinkel J, Knight SJ, Taylor JC, Crow YJ, Benkirane M, Schuh A. SAMHD1 is mutated

recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. *Blood*. 2014 Feb 13;123(7):1021-31. doi: 10.1182/blood-2013-04-490847.

Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F. Next-Generation Sequencing in Acute Lymphoblastic Leukemia. *Int J Mol Sci*. 2019 Jun 15;20(12). pii: E2929. doi: 10.3390/ijms20122929.

Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. *Blood*. 1983 Apr;61(4):660-6.

Curbo S, Karlsson A. Nelarabine: a new purine analog in the treatment of hematologic malignancies. *Rev Recent Clin Trials*. 2006 Sep;1(3):185-92.

Daddacha W, Koyen AE, Bastien AJ, Head PE, Dhere VR, Nabeta GN, Connolly EC, Werner E, Madden MZ, Daly MB, Minten EV, Whelan DR, Schlafstein AJ, Zhang H, Anand R, Doronio C, Withers AE, Shepard C, Sundaram RK, Deng X, Dynan WS, Wang Y, Bindra RS, Cejka P, Rothenberg E, Doetsch PW, Kim B, Yu DS. SAMHD1 Promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. *Cell Rep*. 2017 Aug 22;20(8):1921-1935. doi: 10.1016/j.celrep.2017.08.008.

de Silva S, Hoy H, Hake TS, Wong HK, Porcu P, Wu L. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. *J Biol Chem*. 2013 Mar 29;288(13):9284-92. doi: 10.1074/jbc.M112.447201.

Dikic I. Proteasomal and Autophagic Degradation Systems. *Annu Rev Biochem*. 2017 Jun 20;86:193-224. doi: 10.1146/annurev-biochem-061516-044908.

Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. *Cancer Res*. 2017 Apr 15;77(8):2102-2111. doi: 10.1158/0008-5472.CAN-16-2548.

Follini E, Marchesini M, Roti G. Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia. *Int J Mol Sci.* 2019 Jun 20;20(12). pii: E3021. doi: 10.3390/ijms20123021.

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaña JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. *Nat Med.* 2017 Feb;23(2):256-263. doi: 10.1038/nm.4265.

Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, Helleday T, Henter JI, Schaller T. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. *Cell Cycle.* 2017 Jun 3;16(11):1029-1038. doi: 10.1080/15384101.2017.1314407.

Herold T, Baldus CD, Gökbuget N. Ph-like acute lymphoblastic leukemia in older adults. *N Engl J Med.* 2014 Dec 4;371(23):2235. doi: 10.1056/NEJMc1412123#SA1.

Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, Konstandin NP, Greif PA, Bräundl K, Ksienzyk B, Huk N, Schneider I, Zellmeier E, Jurinovic V, Mansmann U, Hiddemann W, Mullighan CG, Bohlander SK, Spiekermann K, Hoelzer D, Brüggemann M, Baldus CD, Dreyling M, Gökbuget N. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. *Haematologica.* 2017 Jan;102(1):130-138. doi: 10.3324/haematol.2015.136366.

Hollenbaugh JA, Shelton J, Tao S, Amiralaie S, Liu P, Lu X, Goetze RW, Zhou L, Nettles JH, Schinazi RF, Kim B. Substrates and Inhibitors of SAMHD1. *PLoS One*. 2017 Jan 3;12(1):e0169052. doi: 10.1371/journal.pone.0169052.

Homminga I, Zwaan CM, Manz CY, Parker C, Bantia S, Smits WK, Higginbotham F, Pieters R, Meijerink JP. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. *Blood*. 2011 Aug 25;118(8):2184-90. doi: 10.1182/blood-2011-02-337840.

Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. *Nature*. 2011 Jun 29;474(7353):658-61. doi: 10.1038/nature10195.

Huang FW, Feng FY. A Tumor-Agnostic NTRK (TRK) Inhibitor. *Cell*. 2019 Mar 21;177(1):8. doi: 10.1016/j.cell.2019.02.049.

Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannon Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. *Lancet Oncol*. 2015 Nov;16(15):1547-1555. doi: 10.1016/S1470-2045(15)00207-7.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive

acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

Jaén RI, Prieto P, Casado M, Martín-Sanz P, Boscá L. Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: An update. World J Gastroenterol. 2018 Dec 28;24(48):5454-5461. doi: 10.3748/wjg.v24.i48.5454.

Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017 Jan;10(1):1-8. doi: 10.1080/17474086.2017.1262757.

Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug;4(8):e387-e398. doi: 10.1016/S2352-3026(17)30103-5.

Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, Tofoleanu F, Reiss K, Ferreirós N, Geisslinger G, Batista VS, Ji X, Cinatl J Jr, Keppler OT, Xiong Y. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10022-E10031. doi: 10.1073/pnas.1805593115.

Ko PJ, Dixon SJ. Protein palmitoylation and cancer. EMBO Rep. 2018 Oct;19(10). pii: e46666. doi: 10.15252/embr.201846666.

Laguet N, Sobhian B, Casartelli N, Ringiard M, Chable-Bessia C, Ségéral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-

specific HIV-1 restriction factor counteracted by Vpx. *Nature*. 2011 May 25;474(7353):654-7. doi: 10.1038/nature10117.

Luoh SW, Flaherty KT. When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. *Ann Intern Med*. 2018 Aug 21;169(4):233-239. doi: 10.7326/M17-2832.

Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. *Blood*. 2017 Mar 2;129(9):1134-1142. doi: 10.1182/blood-2016-07-692608.

Mauney CH, Hollis T. SAMHD1: Recurring roles in cell cycle, viral restriction, cancer, and innate immunity. *Autoimmunity*. 2018 May;51(3):96-110. doi: 10.1080/08916934.2018.1454912.

Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic Acids Res*. 2019 Jan 8;47(D1):D419-D426. doi: 10.1093/nar/gky1038.

Michaelis M, Wass MN, Cinatl J Jr. Drug-adapted cancer cell lines as preclinical models of acquired resistance. *Cancer Drug Resist*. 2019; 2:447-456. doi: 10.20517/cdr.2019.005

Mohseni M, Uludag H, Brandwein JM. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. *Am J Blood Res*. 2018 Dec 10;8(4):29-56.

Momparler RL, Fischer GA. Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. *J Biol Chem*. 1968 Aug 25;243(16):4298-304.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983 Dec 16;65(1-2):55-63.

Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, Schliemann C, Bohnenberger H, Angenendt L, Hartmann W, Wardelmann E, Rothenburger T, Mohr S, Scheich S, Comoglio F, Wilke A, Ströbel P, Serve H, Michaelis M, Ferreirós N, Geisslinger G, Xiong Y, Keppler OT, Cinatl J Jr. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. *Nat Commun.* 2019 Aug 2;10(1):3475.

Onafuye H, Pieper S, Mulac D, Cinatl J Jr, Wass MN, Langer K, Michaelis M. Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. *Beilstein J Nanotechnol.* 2019 Aug 14;10:1707-1715. doi: 10.3762/bjnano.10.166.

Pavlovic S, Kotur N, Stankovic B, Zukic B, Gasic V, Dokmanovic L. Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment. *Genes (Basel).* 2019 Mar 1;10(3). pii: E191. doi: 10.3390/genes10030191.

Radhakrishnan A, Green R. Connections Underlying Translation and mRNA Stability. *J Mol Biol.* 2016 Sep 11;428(18):3558-64. doi: 10.1016/j.jmb.2016.05.025.

Rentoft M, Lindell K, Tran P, Chabes AL, Buckland RJ, Watt DL, Marjavaara L, Nilsson AK, Melin B, Trygg J, Johansson E, Chabes A. Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. *Proc Natl Acad Sci U S A.* 2016 Apr 26;113(17):4723-8. doi: 10.1073/pnas.1519128113.

Rodriguez CO Jr, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. *Cancer Res.* 2002 Jun 1;62(11):3100-5.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis

M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. *Nat Med.* 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255.

Shewach DS, Mitchell BS. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells. *Cancer Res.* 1989 Dec 1;49(23):6498-502.

Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P, Janka-Schaub GE, Armstrong SA, Korsmeyer SJ, Pieters R. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. *Blood.* 2003 Feb 15;101(4):1270-6.

Teachey DT, O'Connor D. How I Treat Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma in Children. *Blood.* 2019 Nov 18. pii: blood.2019001557. doi: 10.1182/blood.2019001557.

Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N. Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. *Cancers (Basel).* 2018 Jul 23;10(7). pii: E240. doi: 10.3390/cancers10070240.

Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. *Cancer Res.* 1985 Aug;45(8):3646-50.

Wolf DH, Menssen R. Mechanisms of cell regulation - proteolysis, the big surprise. *FEBS Lett.* 2018 Aug;592(15):2515-2524. doi: 10.1002/1873-3468.13109.

Wittmann S, Behrendt R, Eissmann K, Volkmann B, Thomas D, Ebert T, Cribier A, Benkirane M, Hornung V, Bouzas NF, Gramberg T. Phosphorylation of murine

SAMHD1 regulates its antiretroviral activity. *Retrovirology*. 2015 Dec 15;12:103. doi: 10.1186/s12977-015-0229-6.

Wu C, Li W. Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia. *Crit Rev Oncol Hematol*. 2018 Jun;126:100-111. doi: 10.1016/j.critrevonc.2018.04.002.

Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJ. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res*. 2013 Jan;41(Database issue):D955-61. doi: 10.1093/nar/gks1111.

Zwaan CM, Kowalczyk J, Schmitt C, Bielora B, Russo MW, Woessner M, Ranganathan S, Leverger G. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. *Br J Haematol*. 2017 Oct;179(2):284-293. doi: 10.1111/bjh.148

Figure legends

Figure 1. Gene expression profiles and nelarabine sensitivity in acute lymphoblastic leukaemia (ALL) cell lines. A) Nelarabine sensitivity expressed as area under the curve (AUC) in T-cell precursor ALL (T-ALL) and B-ALL cell lines from CTRP. B) Heatmap illustrating expression patterns of genes differentially regulated between T-ALL and B-ALL cell lines based on CTRP data. Heatmaps displaying the expression of all genes in the CTRP ALL cell lines and those displaying gene expression in the ALL cell lines in the CCLE and GDSC datasets are provided in Suppl. Figure 1. Individual gene expression values are presented in Suppl. Table 3.

Figure 2. Comparison of SAMHD1 expression (mRNA abundance) levels in T-ALL and B-ALL cell lines from the CTRP, CCLE, and GDSC (A) and in blasts from leukaemia patients (B). C) Comparison of the expression of other genes known to affect nucleoside analogue activity based on CTRP data. Respective CCLE and GDSC data are provided in Suppl. Figure 3. * p-values for the comparison B-ALL vs. T-ALL

Figure 3. Comparison of nelarabine (CTRP) and cytarabine (CTRP, GDSC) sensitivity between B-ALL and T-ALL cell lines and correlation of SAMHD1 mRNA levels with the nelarabine and cytarabine sensitivity (expressed as AUC) across all B-ALL and T-ALL cell lines. Pearson's r values and respective p-values are provided.

Respective data on the correlation of *SAMHD1* expression with drug sensitivity exclusively for B-ALL and T-ALL cell lines are provided in Suppl. Figure 4 (nelarabine) and Suppl. Figure 5 (cytarabine).

Figure 4. SAMHD1 protein and mRNA levels in the RCCL panel of T-ALL and B-ALL cell lines. A) Representative Western blots indicating protein levels of total SAMHD1 and phosphorylated SAMHD1 (p-SAMHD1). GAPDH was used as loading control. THP-1 is an acute myeloid leukaemia cell line characterised by high cellular SAMHD1 levels [Schneider et al., 2017], which served as positive control. B) Quantitative SAMHD1 protein levels (quantified using near-infrared Western blot images to determine the ratio SAMHD1/ GAPDH relative to the positive control THP-1) and SAMHD1 mRNA abundance levels (as determined by qPCR) in T-ALL and B-ALL cell lines.

Figure 5. AraG and cytarabine concentrations that reduce the viability of the RCCL ALL cell lines by 50% (IC50) and correlation of the IC50s with the cellular SAMHD1 protein or mRNA levels. Numerical data are provided in Suppl. Table 5.


Figure 6. Effect of SAMHD1 on nelarabine and cytarabine sensitivity in ALL and AML cells. A) Dose-response curves of AraG- and cytarabine-treated ALL cell lines in the absence or presence of Vpx virus-like particles (cause SAMHD1 depletion), or Vpr virus-like particles (negative) controls. Concentrations that reduce ALL cell viability by 50% (IC50s) and Western blots confirming SAMHD1 depletion are provided. B) Effects of AraG and cytarabine on AML cell lines in the absence or presence of functional SAMHD1. In the *SAMHD1*-expressing AML cell line THP-1, the *SAMHD1* gene was disrupted by CRISPR/Cas9 (THP1-KO). The non-*SAMHD1* expressing AML cell line HEL and the non-*SAMHD1* expressing ALL cell line JURKAT were transduced with wild-type *SAMHD1* (SAMHD1_WT) or the triphosphohydrolase-defective *SAMHD1*

mutant D311A (SAMHD1_D311A). Dose-response curves, drug concentrations that reduce cell viability by 50% (IC50s), and Western blots confirming SAMHD1 protein levels are provided.

Figure 7. *SAMHD1* promoter methylation in ALL cell lines. A) Analysis of *SAMHD1* promoter methylation in the RCCL cell line panel through amplification of a single PCR product (993-bp) corresponding to the promoter sequence after HpaII digestion. A 0.25-kb fragment of the GAPDH gene lacking HpaII sites was PCR-amplified using the same template DNA served as loading control. B) GDSC data indicating *SAMHD1* promoter methylation in B-ALL and T-ALL cell lines and correlation of *SAMHD1* promoter methylation and *SAMHD1* expression across all ALL cell lines. C) GDSC data indicating the level of global methylation in B-ALL and T-ALL cell lines.

Figure 1


A




B

Differentially regulated genes in B-ALL and T-ALL cell lines (CTRP)

Gene expression
(log2 RMA normalised)



Gene



C




Figure 2




Figure 3





Figure 4

A



B




Figure 5





Figure 6

A



B







Figure 7



B SAMHD1 promotor methylation



C Global methylation

